Search

Xenon Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

63.11 -1.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

62.74

Massimo

64.15

Metriche Chiave

By Trading Economics

Entrata

3M

-102M

EPS

-1.17

Dipendenti

358

EBITDA

-7.6M

-112M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+23.11% upside

Dividendi

By Acuity

Utili prossimi

2 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

471M

6B

Apertura precedente

64.73

Chiusura precedente

63.11

Xenon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 ago 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 ago 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

5 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc. shares are higher in after-market hours amid notable volatility, though no specific news was identified to explain the movement.

4 ago 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are trading lower during after-market hours, breaking a recent trend of higher daily closes since Tuesday.

3 ago 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31 lug 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30 lug 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29 lug 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28 lug 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27 lug 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24 lug 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23 lug 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22 lug 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21 lug 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20 lug 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Xenon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

23.11% in crescita

Previsioni per 12 mesi

Media 78 USD  23.11%

Alto 90 USD

Basso 63 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Xenon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

12

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat